These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 15581262)

  • 61. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Wilens TE; Greenhill LL; Gao H; Baker KD; Feldman PD; Gelowitz DL
    J Am Acad Child Adolesc Psychiatry; 2006 Aug; 45(8):919-927. PubMed ID: 16865034
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder.
    Ghuman JK; Aman MG; Ghuman HS; Reichenbacher T; Gelenberg A; Wright R; Rice S; Fort C
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):155-66. PubMed ID: 19364293
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder.
    Durell TM; Pumariega AJ; Rothe EM; Tamayo JM; Baron D; Williams D
    Ann Clin Psychiatry; 2009; 21(1):26-37. PubMed ID: 19239830
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Mayfield-Jorgensen ML; March JS; Kollins SH; Murray DW; Ravi H; Greenhill LL; Kotler LA; Paykina N; Biggins P; Stoner J
    J Child Adolesc Psychopharmacol; 2007 Apr; 17(2):175-85. PubMed ID: 17489712
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder].
    Velásquez-Tirado JD; Peña JA
    Rev Neurol; 2005 Oct 16-31; 41(8):493-500. PubMed ID: 16224736
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.
    Cardo E; Porsdal V; Quail D; Fuentes J; Steer C; Montoya A; Anand E; Escobar R
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):252-61. PubMed ID: 23683140
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
    Slatkoff J; Greenfield B
    Expert Opin Investig Drugs; 2006 Jun; 15(6):649-67. PubMed ID: 16732717
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
    Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):353-63. PubMed ID: 23083022
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
    Tanaka Y; Rohde LA; Jin L; Feldman PD; Upadhyaya HP
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):262-70. PubMed ID: 23683141
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
    Montoya A; Escobar R; García-Polavieja MJ; Lachno DR; Alda JÁ; Artigas J; Cardo E; García M; Gastaminza X; Gilaberte I
    J Child Neurol; 2011 Jan; 26(1):31-6. PubMed ID: 20525942
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.